REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Peptide Library

ACE-031

ACVR2B-Fc / ActRIIB-Fc

Growth Factors

ACE-031 is a soluble form of the activin receptor type IIB (ActRIIB) fused to an IgG1 Fc domain, developed by Acceleron Pharma as a decoy receptor to trap myostatin and related TGF-beta ligands before they can signal through their natural receptors. By sequestering myostatin, activin A, and GDF-11, it was designed to promote muscle growth and inhibit muscle wasting. Clinical development was discontinued due to safety concerns including epistaxis and telangiectasias observed in Duchenne muscular dystrophy trials.

Mechanism of Action

Soluble activin receptor type IIB fusion protein that acts as a decoy receptor, binding and neutralizing myostatin, activin, GDF-11, and other TGF-beta superfamily ligands. Removes multiple negative regulators of muscle growth simultaneously.

Research Protocols

For research purposes only. Not medical advice.

Clinical trial protocols used 0.3-3mg/kg intravenously every 2 weeks. Research was halted after Phase 2 due to epistaxis and telangiectasia in Duchenne muscular dystrophy patients.

Research Notes

Clinical Research Status

ACE-031 completed a Phase 2 trial in boys with Duchenne muscular dystrophy (DMD) but was discontinued in 2011 after safety signals including nosebleeds, gum bleeding, and skin telangiectasias (dilated blood vessels) emerged. A Phase 1 trial in healthy postmenopausal women demonstrated dose-dependent increases in lean body mass and thigh muscle volume. Acceleron subsequently developed ACE-083 (a locally-acting version) and ACE-2494 with modified selectivity, though neither has achieved approval for muscle indications.

Key Published Findings

The Phase 1 trial showed a single dose of ACE-031 increased lean body mass by up to 1.0 kg and decreased fat mass, with sustained effects over 4 weeks post-dose. The DMD Phase 2 trial was halted after dose-limiting vascular effects (epistaxis, telangiectasia) were observed at higher doses. Research determined that the broad ligand-trapping profile, particularly inhibition of BMP-9 and BMP-10 (which regulate vascular homeostasis), caused the vascular adverse effects rather than myostatin inhibition itself.

Safety Profile

The primary safety concern was vascular effects attributed to BMP-9/10 inhibition: epistaxis (nosebleeds), telangiectasias, and gum bleeding, which are manifestations of disrupted vascular integrity similar to hereditary hemorrhagic telangiectasia. These vascular effects were dose-dependent and reversible upon discontinuation. The lesson from ACE-031's failure is that broadly targeting the ActRIIB ligand family produces unacceptable off-target vascular effects, necessitating more selective approaches to myostatin inhibition.

Comparison to Related Compounds

ACE-031's broad ligand trap approach contrasts with more selective myostatin-specific antibodies (stamulumab, domagrozumab) that avoid BMP-9/10 inhibition. Follistatin similarly neutralizes multiple TGF-beta family members but through a different mechanism and has not shown the same vascular toxicity pattern. Acceleron's subsequent ACE-083, a locally-injected compound, attempted to avoid systemic vascular effects but was also discontinued in FSHD trials due to insufficient efficacy.

Community Observations

ACE-031's clinical failure is frequently cited as a cautionary example of how broad-spectrum target approaches in the myostatin pathway carry unpredictable risks from inhibiting related ligands. The compound demonstrated that pure myostatin inhibition alone may not be sufficient for clinically meaningful muscle gains, while non-selective approaches produce unacceptable side effects. Researchers have largely moved toward more targeted approaches (anti-myostatin antibodies, bimagrumab targeting ActRII directly) informed by ACE-031's failure mode.

Half-Life

~10-15 days

Reconstitution

Sterile saline for IV infusion

Storage

Lyophilized

Store at -20C. Protect from light.

Reconstituted

Prepare fresh for each administration.

US Legal Status

Research chemical (clinical trials halted)

Also Known As

ACVR2B-FcActRIIB-Fc

PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer